Stock AnalizLantheus Holdings, Inc. LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2015 · data as of November 13, 2026
Lantheus Holdings, Inc. (LNTH) is a healthcare company listed in the US with a market value of about $6.6B. In the twelve months to September 30, 2026 it had revenue of $1.6B and net income of $270M, a net margin of 17.3%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (1/5).
Key numbers: a P/E of 25.1, a price to free cash flow of 16.9, 5-year revenue growth of 35% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 35% below the current price.
Score: 2.6 / 5
Checks passed
- P/FCF below 20
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6B | $1.5B | $1.5B | $1.3B | $935M | $425M | $339M | $347M | $343M | $331M | $302M |
| Net income | $270M | $234M | $312M | $327M | $28M | -$71M | -$13M | $32M | $41M | $123M | $27M |
| Free cash flow | $393M | $354M | $493M | $260M | $22M | $54M | $16M | $58M | $41M | $37M | $42M |
| EPS (diluted) | $4.05 | $3.41 | $4.36 | $4.65 | $0.40 | $-1.06 | $-0.25 | $0.79 | $1.03 | $3.17 | $0.82 |
| Net margin | 17.3% | 15.2% | 20.4% | 25.2% | 3.0% | -16.8% | -4.0% | 9.1% | 11.8% | 37.2% | 8.9% |
| ROIC | — | 13.5% | 19.4% | 20.2% | 2.8% | -8.8% | -0.4% | 13.2% | 15.6% | 14.1% | 31.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $105.99, 4% above the current price; targets range from $102.50 to $115.00; the consensus rating is “Hold”; expected EPS is $6.19 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Lantheus’s P/E ratio?
About 25.1, based on the last twelve months of diluted earnings per share (forward P/E about 16.0).
Is Lantheus stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 35% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Lantheus pay a dividend?
Not currently.
Is Lantheus a good stock to buy?
We do not give buy or sell advice. Lantheus scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.